Group 1: Company Performance - 24 innovative drug companies reported their 2025 performance, with 19 achieving positive net profit, representing 79.17% [1] - BeiGene achieved its first annual profit in 2025 with a net profit of 1.422 billion yuan, and total revenue of 38.205 billion yuan, a 40.4% increase year-on-year [1] - Microbio achieved a total revenue of 910 million yuan in 2025, a 38.24% increase, and a net profit of 51.0757 million yuan, marking a turnaround [2] - Shanghai Yizhong reported a revenue of 317 million yuan, an 82.72% increase, and a net profit of 64.132 million yuan, a significant 819.42% increase [2] Group 2: Industry Trends - The overall performance of the innovative drug industry is improving, but significant differentiation exists, with many companies still in a loss-reduction phase [1] - The continuous release of policy dividends is a key driver for performance growth, with nearly 80% of innovative drugs entering the medical insurance directory within two years [2] - The global healthcare industry saw a financing amount of 63.882 billion USD in 2025, a 10.13% increase, while domestic financing in the healthcare sector reached 73.777 billion yuan, a 39.05% increase [3] - The number of new drug IND applications in China reached 2,175 in 2025, an 8.8% increase [3]

微芯生物表示，基于对公司未来发展的信心和对公司价值的认可，并结合公司经营状况、主营业务发展 前景、财务状况等因素，为维护广大投资者利益，增强投资者信心，公司董事长XIANPING LU提议公 司以自有资金和自筹资金回购已发行的部分人民币普通股（A股）股票，在未来适宜时机全部用于员工 持股计划或股权激励。 北京商报讯（记者 丁宁）2月27日晚间，微芯生物（688321）发布公告称，公司董事会于2月27日收到 公司董事长XIANPING LU 《关于提议深圳微芯生物科技股份有限公司回购公司股份的函》， XIANPING LU提议公司使用自有资金和自筹资金以集中竞价交易方式进行股份回购。本次回购资金总 额不低于8000万元（含），不超过1.2亿元（含）。 ...

Group 1: Company Performance - Cambrian achieved a net profit of 2.059 billion yuan in 2025, turning a profit due to a significant increase in revenue, which reached 6.497 billion yuan, a 453.21% increase year-on-year [1] - Muxi reported a total revenue of 1.644 billion yuan in 2025, a 121.26% increase, with net losses narrowing by 44.53% to 781.45 million yuan [2] - Moer Thread's revenue grew by 243.37% to 1.506 billion yuan in 2025, with net losses reduced by 36.70% to 1.024 billion yuan [3] - Lingdian Electric Control's net profit increased by 745.02% to 135 million yuan, despite a slight revenue decrease of 0.17% to 1.194 billion yuan [4] - JinkoSolar reported a net loss of 6.786 billion yuan in 2025, a decrease of 6,959.50%, with total revenue falling by 29.18% to 65.492 billion yuan [16] Group 2: Corporate Actions - Huicheng is planning to issue H-shares and list on the Hong Kong Stock Exchange, with details still under discussion [5] - Zhongying Technology is planning to acquire at least 51% of Yingzhong Electric, which is expected to constitute a major asset restructuring [7] - Jierong Technology's actual controller is under investigation for suspected violations of information disclosure laws [6] Group 3: Market and Industry Trends - The AI industry is driving demand for computing power, benefiting companies like Cambrian and Moer Thread, which are expanding their market presence [1][3] - Muxi's GPU product shipments have significantly increased, reflecting strong market recognition and demand [2] - The global photovoltaic industry is facing price fluctuations and trade protection policies, impacting JinkoSolar's profitability [16]

每经AI快讯，2月27日，微芯生物公告，公司董事长XIANPINGLU博士于2026年2月27日提议公司以自 有资金和自筹资金，通过集中竞价交易方式回购公司股份，回购资金总额不低于8000万元、不超过 12000万元，即0.80亿~1.20亿元；回购股份将用于员工持股计划或股权激励。若3年内未使用完毕，剩 余股份将予以注销。 ...

证券代码：688321 证券简称：微芯生物 公告编号： 2026-015 深圳微芯生物科技股份有限公司 关于公司董事长提议回购股份的公告 1、回购股份的种类：公司发行的人民币普通股（A 股） 2、回购股份的用途：用于员工持股计划或股权激励。若公司未能 在股份回购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份， 尚未使用的已回购股份将予以注销 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"）董事会于 2026 年 2 月 27 日收到公司董事长 XIANPING LU 博士《关于提议深圳微 芯生物科技股份有限公司回购公司股份的函》，XIANPING LU 博士提议 公司使用自有资金和自筹资金以集中竞价交易方式进行股份回购，具体 如下： 一、 提议人的基本情况及提议时间 提议人：公司董事长 XIANPING LU 博士 提议时间：2026 年 2 月 27 日 二、 提议回购股份的原因及目的 基于对公司未来发展的信心和对公司价值的认可，并结合公司经营 状况、主营业务发展前 ...

格隆汇2月27日｜微芯生物公告，董事长XIANPINGLU博士提议公司使用自有资金和自筹资金以集中竞 价交易方式进行股份回购，回购资金总额不低于人民币8000万元（含），不超过人民币1.2亿元 （含），回购价格不高于公司董事会审议通过回购股份方案前30个交易日公司股票交易均价的150%。 ...

Core Viewpoint - The company reported significant growth in its 2025 annual performance, with notable increases in revenue and net profit, driven by successful commercialization of its products and strategic partnerships [3][4]. Financial Data Summary - The company's 2025 annual operating revenue reached 909.54 million yuan, with a total profit of 50.84 million yuan and a net profit attributable to shareholders of 51.08 million yuan [3]. - The net profit after deducting non-recurring gains and losses was 38.36 million yuan, and the earnings per share stood at 0.1252 yuan [3]. Performance Drivers - The product Siglepag's unique clinical value contributed to a significant sales revenue increase of approximately 122% year-on-year, supported by self-operated channels, strategic partnerships, and new retail initiatives [4]. - The product Sidaben's clinical value received recognition from the National Medical Insurance Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory, leading to a sales revenue increase of about 16% year-on-year [4]. Growth Metrics - The company's total operating revenue grew by 38.24%, with operating profit, total profit, net profit attributable to shareholders, net profit after deducting non-recurring gains and losses, and basic earnings per share increasing by 128.52%, 152.57%, 144.58%, 118.69%, and 144.59% respectively [5].

证券日报网讯 2月26日，微芯生物发布2025年度业绩快报公告称，公司2025年实现营业总收入90953.78 万元，同比增长38.24%；归属于上市公司股东的净利润5107.57万元。 （文章来源：证券日报） ...

证券代码：688321 证券简称：微芯生物 公告编号：2026-014 深圳微芯生物科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司2025年年度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 1 单位：万元 项目 本报告期 上年同期 增减变动幅度（％） 营业总收入 90,953.78 65,794.94 38.24 营业利润 5,090.29 -17,850.28 128.52 利润总额 5,084.33 -9,671.19 152.57 归属于母公司所有者的净利润 5,107.57 -11,457.06 144.58 归属于母公司所有者的扣除非 经常性损益的净利润 3,835.62 -20,527.78 118.69 基本每股收益（元） 0.1252 -0.2808 144.59 加权平均净资产收益率（%） 3.18 -6.97 增加 10.15 个百分点 本 ...

Core Viewpoint - Micron Biomedical (688321.SH) reported a significant turnaround in its financial performance for the fiscal year 2025, achieving a net profit of 51.08 million yuan, driven by strong sales growth in its key products [1] Financial Performance - The company's total operating revenue for 2025 reached 909.54 million yuan [1] - Total profit amounted to 50.84 million yuan [1] - Net profit attributable to shareholders was 51.08 million yuan, marking a return to profitability [1] - The net profit after deducting non-recurring gains and losses was 38.36 million yuan [1] - Earnings per share stood at 0.1252 yuan [1] Product Performance - Sales revenue for the product Sigleptin Sodium increased by approximately 122% year-on-year, attributed to its unique clinical value in "diabetes and liver management" and effective commercialization strategies [1] - Sales revenue for the product Sidabenamine grew by around 16% year-on-year, supported by its recognition in the National Medical Insurance Directory and the addition of a new indication for diffuse large B-cell lymphoma [1] - The product Sidabenamine was included in the latest version of the National Medical Insurance Directory under regular Class B management, which positively impacted its sales despite price reductions and inventory adjustments in the fourth quarter of 2025 [1]